On Invalid Date, Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 2023 earnings per share (EPS) of $0.39, up 152.7% year over year. Total Eagle Pharmaceuticals earnings for the quarter were $5.16 million. In the same quarter last year, Eagle Pharmaceuticals's earnings per share (EPS) was -$0.74.
As of Q1 2024, Eagle Pharmaceuticals's earnings has grown -49.73% year over year. This is 61.53 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 11.8%. Eagle Pharmaceuticals's earnings in the past year totalled $11.95 million.
What is EGRX's earnings date?
Eagle Pharmaceuticals's earnings date is Invalid Date. Add EGRX to your watchlist to be reminded of EGRX's next earnings announcement.
What was EGRX's revenue last quarter?
On Invalid Date, Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 2023 revenue of $64.65 million up 12.8% year over year. In the same quarter last year, Eagle Pharmaceuticals's revenue was $74.14 million.
What was EGRX's revenue growth in the past year?
As of Q1 2024, Eagle Pharmaceuticals's revenue has grown -5.38% year over year. This is 15.09 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 9.72%. Eagle Pharmaceuticals's revenue in the past year totalled $257.55 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.